James P. Mancuso

4.5k total citations · 2 hit papers
42 papers, 3.3k citations indexed

About

James P. Mancuso is a scholar working on Endocrinology, Diabetes and Metabolism, Molecular Biology and Surgery. According to data from OpenAlex, James P. Mancuso has authored 42 papers receiving a total of 3.3k indexed citations (citations by other indexed papers that have themselves been cited), including 34 papers in Endocrinology, Diabetes and Metabolism, 25 papers in Molecular Biology and 14 papers in Surgery. Recurrent topics in James P. Mancuso's work include Diabetes Treatment and Management (29 papers), Metabolism, Diabetes, and Cancer (24 papers) and Pancreatic function and diabetes (8 papers). James P. Mancuso is often cited by papers focused on Diabetes Treatment and Management (29 papers), Metabolism, Diabetes, and Cancer (24 papers) and Pancreatic function and diabetes (8 papers). James P. Mancuso collaborates with scholars based in United States, Sweden and Canada. James P. Mancuso's co-authors include Steven G. Terra, Susan Huyck, Richard E. Pratley, Darren K. McGuire, Christopher P. Cannon, Urszula Masiukiewicz, Weichung Shih, B Charbonnel, Francesco Cosentino and Robert Frederich and has published in prestigious journals such as New England Journal of Medicine, Circulation and Journal of the American College of Cardiology.

In The Last Decade

James P. Mancuso

41 papers receiving 3.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes

2020 1.0k citations Christopher P. Cannon, Richard E. Pratley et al. New England Journal of Medicine profile →
Effects of an Inhibitor of Cholesteryl Ester Transfer Protein on HDL Cholesterol

2004 574 citations Margaret E. Brousseau, Ernst J. Schaefer et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
James P. Mancuso United States	20	2.6k	1.4k	1.1k	514	409	42	3.3k
Adie Viljoen United Kingdom	25	1.9k 0.7×	873 0.6×	1.1k 1.0×	300 0.6×	247 0.6×	98	3.3k
Robert Ćhilton United States	30	1.6k 0.6×	756 0.5×	882 0.8×	748 1.5×	208 0.5×	122	2.8k
Teresa Maria Seccia Italy	33	2.0k 0.8×	1.7k 1.2×	503 0.4×	883 1.7×	281 0.7×	132	3.2k
Erica L. Goodrich United States	20	2.5k 1.0×	1.3k 0.9×	1.0k 0.9×	1.2k 2.3×	467 1.1×	54	3.6k
Klaus A. Dugi Germany	39	2.9k 1.1×	1.6k 1.1×	1.4k 1.3×	741 1.4×	170 0.4×	72	4.4k
Stephen D. Wiviott United States	28	1.4k 0.5×	1.6k 1.2×	656 0.6×	1.4k 2.8×	248 0.6×	68	3.5k
Paul D. Rosenblit United States	19	2.5k 1.0×	1.3k 0.9×	864 0.8×	557 1.1×	101 0.2×	31	3.7k
Andrew Lewin United States	23	3.3k 1.3×	1.3k 1.0×	1.3k 1.2×	738 1.4×	277 0.7×	57	4.3k
Steven G. Terra United States	27	3.4k 1.3×	1.2k 0.9×	1.9k 1.7×	902 1.8×	575 1.4×	78	4.2k
Martin I. Freed United States	27	2.1k 0.8×	673 0.5×	1.9k 1.7×	549 1.1×	195 0.5×	48	4.3k

Countries citing papers authored by James P. Mancuso

Since Specialization

Citations

This map shows the geographic impact of James P. Mancuso's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by James P. Mancuso with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites James P. Mancuso more than expected).

Fields of papers citing papers by James P. Mancuso

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by James P. Mancuso. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by James P. Mancuso. The network helps show where James P. Mancuso may publish in the future.

Co-authorship network of co-authors of James P. Mancuso

This figure shows the co-authorship network connecting the top 25 collaborators of James P. Mancuso. A scholar is included among the top collaborators of James P. Mancuso based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with James P. Mancuso. James P. Mancuso is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Schwartz, Pamela F., et al.. (2025). Comprehensive implementations of multiple imputation using retrieved dropouts for continuous endpoints. BMC Medical Research Methodology. 25(1). 47–47. 1 indexed citations

Pandey, Ambarish, Ahmed A. Kolkailah, Robert Frederich, et al.. (2025). Heart Failure Outcomes Captured by Adverse Event Reporting in Participants with Type 2 Diabetes and Atherosclerotic Cardiovascular Disease: Observations from the VERTIS CV Trial. European Journal of Heart Failure. 27(3). 521–526. 1 indexed citations

Sridhar, Vikas S., Francesco Cosentino, Samuel Dagogo‐Jack, et al.. (2024). Effects of ertugliflozin on uric acid and gout‐related outcomes in persons with type 2 diabetes and cardiovascular disease: Post hoc analyses from VERTIS CV. Diabetes Obesity and Metabolism. 26(11). 5336–5346. 3 indexed citations

Cosentino, Francesco, Samuel Dagogo‐Jack, Robert Frederich, et al.. (2024). Long‐term weight loss and cardiorenal outcomes by baseline BMI in the VERTIS CV trial. Diabetes Obesity and Metabolism. 27(2). 583–594. 2 indexed citations

Frederich, Robert, et al.. (2023). Imputation of Missing Data for Time-to-Event Endpoints Using Retrieved Dropouts. Therapeutic Innovation & Regulatory Science. 58(1). 114–126. 2 indexed citations

Pandey, Ambarish, Ahmed A. Kolkailah, Francesco Cosentino, et al.. (2023). Ertugliflozin and hospitalization for heart failure across the spectrum of pre-trial ejection fraction: post-hoc analyses of the VERTIS CV trial. European Heart Journal. 44(48). 5163–5166. 3 indexed citations

Inzucchi, Silvio E., Ian J. Neeland, James P. Mancuso, et al.. (2022). Ertugliflozin and incident obstructive sleep apnea: an analysis from the VERTIS CV trial. Sleep And Breathing. 27(2). 669–672. 27 indexed citations

Cosentino, Francesco, Christopher P. Cannon, David Z.I. Cherney, et al.. (2020). Efficacy of Ertugliflozin on Heart Failure–Related Events in Patients With Type 2 Diabetes Mellitus and Established Atherosclerotic Cardiovascular Disease. Circulation. 142(23). 2205–2215. 175 indexed citations

Cherney, David Z.I., Hiddo J.L. Heerspink, Robert Frederich, et al.. (2020). Effects of ertugliflozin on renal function over 104 weeks of treatment: a post hoc analysis of two randomised controlled trials. Diabetologia. 63(6). 1128–1140. 33 indexed citations

10.

Patel, Shrita M., Anne Hickman, Robert Frederich, et al.. (2020). Safety of Ertugliflozin in Patients with Type 2 Diabetes Mellitus: Pooled Analysis of Seven Phase 3 Randomized Controlled Trials. Diabetes Therapy. 11(6). 1347–1367. 18 indexed citations

11.

Cannon, Christopher P., Darren K. McGuire, Richard E. Pratley, et al.. (2018). DESIGN AND BASELINE CHARACTERISTICS OF THE EVALUATION OF ERTUGLIFOZIN EFFICACY AND SAFETY CARDIOVASCULAR OUTCOMES TRIAL (VERTIS-CV). Journal of the American College of Cardiology. 71(11). A1825–A1825. 55 indexed citations

12.

Miller, Sam S., Hao Zhou, Susan Huyck, et al.. (2018). Ertugliflozin and Sitagliptin Co-initiation in Patients with Type 2 Diabetes: The VERTIS SITA Randomized Study. Diabetes Therapy. 9(1). 253–268. 70 indexed citations

13.

Huyck, Susan, et al.. (2018). How 4 Companies Became One: Co-development Under an Outsourced Model With Focus on Phase 3 Analysis and Reporting Deliverables. Therapeutic Innovation & Regulatory Science. 53(3). 301–306.

14.

Liu, Jie, Lisa Tarasenko, Annpey Pong, et al.. (2018). Efficacy and Safety of Ertugliflozin across Racial Groups in Patients with Type 2 Diabetes Mellitus (T2DM). Diabetes. 67(Supplement_1). 1 indexed citations

15.

Hollander, Priscilla, Jie Liu, Julie Hill, et al.. (2017). Ertugliflozin Compared with Glimepiride in Patients with Type 2 Diabetes Mellitus Inadequately Controlled on Metformin: The VERTIS SU Randomized Study. Diabetes Therapy. 9(1). 193–207. 88 indexed citations

16.

Grunberger, George, Jeremy Johnson, Susan Huyck, et al.. (2017). Ertugliflozin in Patients with Stage 3 Chronic Kidney Disease and Type 2 Diabetes Mellitus: The VERTIS RENAL Randomized Study. Diabetes Therapy. 9(1). 49–66. 111 indexed citations

17.

Fountaine, Robert J., Ann E. Taylor, James P. Mancuso, et al.. (2010). Increased Food Intake and Energy Expenditure Following Administration of Olanzapine to Healthy Men. Obesity. 18(8). 1646–1651. 79 indexed citations

18.

Brousseau, Margaret E., John S. Millar, Margaret R. Diffenderfer, et al.. (2009). Effects of cholesteryl ester transfer protein inhibition on apolipoprotein A-II-containing HDL subspecies and apolipoprotein A-II metabolism. Journal of Lipid Research. 50(7). 1456–1462. 14 indexed citations

19.

Brousseau, Margaret E., Ernst J. Schaefer, Megan L. Wolfe, et al.. (2004). Effects of an Inhibitor of Cholesteryl Ester Transfer Protein on HDL Cholesterol. New England Journal of Medicine. 350(15). 1505–1515. 574 indexed citations breakdown →

20.

Mancuso, Jessica, Hongshik Ahn, James J. Chen, & James P. Mancuso. (2002). Age-Adjusted Exact Trend Tests in the Event of Rare Occurrences. Biometrics. 58(2). 403–412. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact